NASDAQ NMS - GLOBAL MARKET · ALZN
-6.45% · -$0.1000 · Vol 118.6K
Market closed · last close 4:00 PM ET · price as of 19:59:30 ET
Alzamend Neuro Inc

Alzamend Neuro Inc

Biotechnology
$1.45
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
ALZN
Alzamend Neuro Inc
Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

89/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALZN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALZN catalysts
About Alzamend Neuro Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
6
Country
US

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.53
Day high
$1.59
Day low
$1.48
Previous close
$1.55
52W high
$2.62
-44.66% from high
52W low
$0.8575
34% of range
Market cap
$7.4M
EPS
$-2.4500
Beta
1.36
Shares out
4.8M
Volume
118.6K
2.17× rel vol
Avg volume
54.7K
VWAP
$1.53
Price history computed in-house
1W
-1.36%
1M
+19.83%
3M
+20.83%
1Y
-39.08%
YTD
-20.33%
SMA 50 $1.28 · above
SMA 200 $1.66 · below
52W position 34%

ALZN overview

Veridion Score
89
Daily close · 2026-08-17
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALZN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALZN Form 4 filings
Public disclosures

Congress activity in ALZN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ALZN in the cached public ledger.

Federal contracts

ALZN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALZN in this window.
Lobbying spend

ALZN lobbying filings, year to date.

Registered lobbying filings matched to Alzamend Neuro Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALZN in this window.
Loading news for ALZN
Analyst ratings
Sovereign unlock shows live analyst consensus for ALZN.
Options
Sovereign unlock shows live options positioning for ALZN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.